Toxicologie

Applications Physostigmine Salicylate is a cholinesterase inhibitor with the potential to improve cognitive ability in individuals with alzheimers. In addition, as a parasympathomimetic, it is used to treat glaucoma, dry mouth, and delayed gastric emptying.
Not a dangerous good if item is equal to or less than 1g/ml and there is less than 100g/ml in the package
References Thal, L. et al.: Neurol., 47, 1389 (1996); Hedner, E. et al.: Eur. J. Oral Sci., 109, 374 (2001);

Applications 2-(Dimethylamino)-4-pyridinyl-boronic Acid can be used to synthesize N-biaryl quinolone carboxylic acids as selective M1 positive allosteric modulators.
References Yang, F., et al.: Bioorg. Med. Chem. Lett., 20, 531 (2010)

Applications (S)-8,14-Dihydroxy Efavirenz, is a metabolite of Efavirenz (E425000), a nonnucleoside HIV-1 reverse transcriptase inhibitor. Antiviral.
References Young, S.D., et al.: Antimicrob. Ag. Chemother., 39, 2602 (1995),

Stability Hygroscopic
Applications Antihypertensive; antiglaucoma
References Al-Shora, H., et al.: Int. J. Pharm., 47, 209 (1988), Golander, Y., et al.: J. Pharm. Sci., 77, 902 (1988),

Applications O-Ethyl Adefovir is an intermediate in the synthesis of Mono-POM Ethyl Adefovir (M567050), which is an analogue of the antiviral drug Adefovir (A247500) with a mono-POM ester protecting group.
References Starrett, J.E. et al.: J. Med. Chem., 37, 1857 (1994);

Impurity Moxifloxacin EP Impurity B
Applications Moxifloxacin (M745000) impurity B.
References Langlois, M., et al.: J. Pharm. Biomed. Anal., 37, 389 (2005), Salem, M., et al.: Chem. Pharm. Bull., 54, 1625 (2006),

Applications (9E)-9-[O-[(4-Methylphenyl)sulfonyl]oxime] Erythromycin is an intermediate in the synthesis of Erythromycin A 9,11-Imino Ether (E650025). Erythromycin A 9,11-Imino Ether is an impurity in the synthesis of Erythromycin (E649950), a macrolide antibiotic with broad spectrum of antibacterial activity.
References Zhang, L. et al.: J. Antibio., 64, 243 (2011); Koch, W.L., et al.: Anal. Profiles Drug Subs., 8, 157 (1979)

Applications An impurity of Moxifloxacin (M745000).
References Tobin, C., et al.: J. Antimicrob. Chemother., 42, 278 (1998),

Applications N-Desdecanoyl, N-(8-Me-decanoyl) Daptomycin is an impurity of Daptomycin (D193350), cyclic lipopeptide antibiotic derived from a fermentation product of Streptomyces roseosporus; disrupts plasma membrane function in gram-positive bacteria. Antibacterial.
References Allen, N.E., et al.: Antimicrob. Agents Chemother., 31, 1093 (1987), Tully, F.P., et al.: Expert Opin. Invest. Drugs, 8, 1223 (1999),

Applications 6-​Fluoro-​3-​[(trimethylsilyl)​oxy]​-2-​pyrazinecarboxamide is an intermediate in synthesizing T-705RTP (T003210), a derivative of T-705 (F103350) which has activity against the lethal H5N1 influenza A viruses. T-705RTP which has the triphosphate group, gets strongly inhibited by the influenza virus RNA polymerase activity in comparison with T-705RMP (T003202).
References Yousuke, F., et al.: Antimicrob Agent Chemother., 49, 981 (2005); Kiso, M., et al.: Proc. Natl. Acad. Sci. U.S.A., 107, 882 (2010);

Applications Dibenzyloxy Tenofovir is an intermediate in the synthesis of Tenofovir Dibenzyloxy Isopropyl Carbamate (T018545); Acyclic phosphonate nucleotide analogue; reverse transcriptase inhibitor. Used as an anti-HIV agent. Antiviral.
References Shaw, J.-P., et al.: Pharm. Res., 14, 1824 (1997), Wyles, D., et al.: Clin Infect. Dis., 40, 174 (2005), Peng, J., et al.: J. Clin. Pharmacol., 46, 265 (2006), Seminari, E., et al.: J. Antimicrob. Chemother., 60, 831 (2007)

Impurity Itraconazole Impurity-1
Applications Des(1-methylpropyl) Itraconazole is an impurity of Itraconazole (I937500). Itraconazole is an orally active antimycotic structurally related to Ketoconazole. Antifungal. It is a COVID19-related research product.
References Espinel-Ingroff, A., et al.: Antimicrob. Agents Chemother., 26, 5 (1984); Heykants, J., et al.: Mycoses, 32, Suppl 1, 67 (1989); Sugar, A.M.,et al.: Curr. Clin. Top. Infect. Dis., 13, 74 (1993);

Applications L-Menthyl 2,2-Dihydroxyacetate is used as a reagent in the synthesis of Lamivudine (L172500); a potent nucleoside reverse transcriptase inhibitor used for the treatment of chronic hepatitis B. L-Menthyl 2,2-Dihydroxyacetate is also used as a reagent in the synthesis of 4-acetoxy-3-hydroxyethylazetidin-2-one, a key intermediate for the preparation of penem and carbapenem antibiotics.
References Morris, D.M., J. Pharm. Biomed. Anal., 12, 255 (1944); Nevens, B.F., et al.: Gastroenterology, 113, 1258 (1997); Perry, C.M., et al.: Drugs, 53, 657 (1977); Goodyear, M.D., et al.: Tetrahedron Lett., 46, 8535 (2005); Kametani, T., et al.: Heterocycles, 25, 241 (1987)

Applications An achiral intermediate of Voriconazole (V760000).
Not a dangerous good if item is equal to or less than 1g/ml and there is less than 100g/ml in the package
References Ferretti, R., et al.: Chromatographia, 47, 649 (1998),

Applications 3’-O-Benzyl Sofosbuvir Desphosphate may be a metabolite of Sofosbuvir (P839640), a prodrug that is metabolized to the active antiviral agent 2'-deoxy-2'-α-fluoro-β-C-methyluridine-5'-monophosphate and is currently being investigated in phase 3 clinical trials for the treatment of hepatitis C. Studies have profiled PSI-7977 as a nucleotide inhibitor of hepatitis C virus, exerting selective inhibitory effects towards HCV NS5B polymerase.
References Lam, A.M.,et al.: Antimicrob. Agents. Chemotherapy., 56, 3359 (2012); Lam, A.M., et al.: J. Virol., 85, 12334 (2011); Sofia, M.J., et al.: J. Medn. Chem., 53, 7202 (2010);

Applications o-Carbomethoxybenzyl Sulfonamide is a useful reactant in organic synthesis.
References Jiang, Lin, et al.: Youji Huaxue, 26(2), 203-206 (2006)

Applications 4-(2-Propyn-1-yloxy) Trimethoprim is an analog of T795615, which is an antibacterial compound and a contaminant of emerging concern (CECs).
References Manius, G.J., et al.: Anal. Profiles Drug Subs., 7, 445 (1978), Roth, B., et al.: J. Med. Chem., 23, 379 (1980), Brogden, R.N., et al.: Drugs, 23, 405 (1982),

Applications Ganciclovir derivative.
References Albers, E., et al.: J. Pharm. Sci., 81, 756 (1992), Dias, C., et al.: J. Pharm. Sci., 91, 6607 (2002), Macha, S., et al.: Drug Metab. Dispos., 30, 670 (2002),